As of 2025-03-16, the Relative Valuation of GT Biopharma Inc (GTBP) is (217.08) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.44 USD, the upside of GT Biopharma Inc based on Relative Valuation is -8996.6%.
The range of the Relative Valuation is (180.64) - (308.67) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 32.6x - 59.9x | 42.7x |
| Forward P/E multiples | 28.0x - 55.7x | 35.7x |
| Fair Price | (180.64) - (308.67) | (217.08) |
| Upside | -7503.2% - -12750.4% | -8996.6% |
| Date | P/E |
| 2025-03-03 | -0.42 |
| 2025-02-28 | -0.43 |
| 2025-02-27 | -0.42 |
| 2025-02-26 | -0.43 |
| 2025-02-25 | -0.44 |
| 2025-02-24 | -0.37 |
| 2025-02-21 | -0.39 |
| 2025-02-20 | -0.38 |
| 2025-02-19 | -0.38 |
| 2025-02-18 | -0.38 |
| 2025-02-14 | -0.39 |
| 2025-02-13 | -0.40 |
| 2025-02-12 | -0.38 |
| 2025-02-11 | -0.38 |
| 2025-02-10 | -0.40 |
| 2025-02-07 | -0.39 |
| 2025-02-06 | -0.40 |
| 2025-02-05 | -0.41 |
| 2025-02-04 | -0.40 |
| 2025-02-03 | -0.41 |
| 2025-01-31 | -0.40 |
| 2025-01-30 | -0.37 |
| 2025-01-29 | -0.38 |
| 2025-01-28 | -0.38 |
| 2025-01-27 | -0.37 |
| 2025-01-24 | -0.44 |
| 2025-01-23 | -0.43 |
| 2025-01-22 | -0.43 |
| 2025-01-21 | -0.42 |
| 2025-01-17 | -0.43 |
| 2025-01-16 | -0.42 |
| 2025-01-15 | -0.42 |
| 2025-01-14 | -0.46 |
| 2025-01-13 | -0.43 |
| 2025-01-10 | -0.48 |
| 2025-01-08 | -0.46 |
| 2025-01-07 | -0.52 |
| 2025-01-06 | -0.54 |
| 2025-01-03 | -0.54 |
| 2025-01-02 | -0.53 |
| 2024-12-31 | -0.55 |
| 2024-12-30 | -0.55 |
| 2024-12-27 | -0.55 |
| 2024-12-26 | -0.56 |
| 2024-12-24 | -0.58 |
| 2024-12-23 | -0.51 |
| 2024-12-20 | -0.32 |
| 2024-12-19 | -0.35 |
| 2024-12-18 | -0.37 |
| 2024-12-17 | -0.45 |